Luminex Corp. (LMNX) Director Kevin M. Mcnamara Sells 12,000 Shares of Stock
Luminex Corp. (NASDAQ:LMNX) Director Kevin M. Mcnamara sold 12,000 shares of Luminex Corp. stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $21.03, for a total value of $252,360.00. Following the sale, the director now owns 67,274 shares of the company’s stock, valued at $1,414,772.22. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Luminex Corp. (NASDAQ:LMNX) traded up 0.24% during trading on Thursday, reaching $20.89. The company’s stock had a trading volume of 80,014 shares. Luminex Corp. has a 1-year low of $17.29 and a 1-year high of $23.75. The stock has a market cap of $910.49 billion, a P/E ratio of 30.81 and a beta of 0.57. The company’s 50 day moving average price is $21.37 and its 200-day moving average price is $21.11.
Luminex Corp. (NASDAQ:LMNX) last posted its quarterly earnings data on Monday, October 31st. The company reported $0.21 EPS for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.09. Luminex Corp. had a return on equity of 11.95% and a net margin of 14.51%. The firm had revenue of $71.20 million for the quarter, compared to analyst estimates of $68.90 million. During the same quarter last year, the company earned $0.22 EPS. The company’s revenue was up 17.5% on a year-over-year basis. Equities analysts forecast that Luminex Corp. will post $0.52 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of LMNX. Teacher Retirement System of Texas raised its position in Luminex Corp. by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 5,429 shares of the company’s stock worth $110,000 after buying an additional 659 shares during the period. ClariVest Asset Management LLC raised its position in shares of Luminex Corp. by 33,173.3% in the third quarter. ClariVest Asset Management LLC now owns 4,991 shares of the company’s stock valued at $113,000 after buying an additional 4,976 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Luminex Corp. by 37.7% in the third quarter. Victory Capital Management Inc. now owns 5,120 shares of the company’s stock valued at $116,000 after buying an additional 1,401 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Luminex Corp. during the third quarter valued at about $143,000. Finally, Mason Street Advisors LLC acquired a new position in shares of Luminex Corp. during the second quarter valued at about $153,000. Hedge funds and other institutional investors own 78.79% of the company’s stock.
Several equities research analysts have recently issued reports on the company. Zacks Investment Research lowered Luminex Corp. from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. Jefferies Group boosted their target price on Luminex Corp. from $21.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 28th. JPMorgan Chase & Co. upgraded Luminex Corp. from an “underweight” rating to a “neutral” rating and boosted their target price for the stock from $18.00 to $22.00 in a report on Thursday, August 18th. Avondale Partners assumed coverage on Luminex Corp. in a report on Wednesday, October 12th. They issued an “outperform” rating and a $27.00 target price for the company. Finally, William Blair restated a “market perform” rating on shares of Luminex Corp. in a report on Tuesday, November 1st. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $23.00.
About Luminex Corp.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.
Receive News & Stock Ratings for Luminex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corp. and related stocks with our FREE daily email newsletter.